Oral or Topical 5-ASA in Ulcerative Colitis

被引:12
作者
Hanauer, Stephen B. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Med, Chicago, IL 60611 USA
关键词
5-Aminosalicylic acid; Mesalamine; Mesalazine; Ulcerative colitis; DOUBLE-BLIND; EFFICACY; 5-AMINOSALICYLATES; MESALAMINE; MESALAZINE; INDUCTION; REMISSION; RELAPSE;
D O I
10.1159/000443026
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aminosalicylates (5-ASAs) are foundational therapies for patients with mild-moderate active ulcerative colitis (UC) and to maintain remissions. A variety of oral and topical formulations have been evaluated in both active and quiescent disease in both extensive and distal UC. This review summarizes data on pharmacokinetics and applications of oral and topical 5-ASA therapies in active and quiescent, extensive colitis and distal disease, both as monotherapies and in combination and reviews dosing and dosing intervals for oral 5-ASA in both active disease and to maintain remissions. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:122 / 124
页数:3
相关论文
共 15 条
[1]  
Cohen RD, 2000, AM J GASTROENTEROL, V95, P1263
[2]   Are There Any Differences in the Efficacy and Safety of Different Formulations of Oral 5-ASA Used for Induction and Maintenance of Remission in Ulcerative Colitis? Evidence from Cochrane Reviews [J].
Feagan, Brian G. ;
Chande, Nilesh ;
MacDonald, John K. .
INFLAMMATORY BOWEL DISEASES, 2013, 19 (09) :2031-2040
[3]   Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis [J].
Flourie, B. ;
Hagege, H. ;
Tucat, G. ;
Maetz, D. ;
Hebuterne, X. ;
Kuyvenhoven, J. P. ;
Tan, T. G. ;
Pierik, M. J. ;
Masclee, A. A. M. ;
Dewit, O. ;
Probert, C. S. ;
Aoucheta, D. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (08) :767-775
[4]   Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis [J].
Ford, Alexander C. ;
Khan, Khurram J. ;
Sandborn, William J. ;
Hanauer, Stephen B. ;
Moayyedi, Paul .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (05) :513-519
[5]   Efficacy of Oral vs. Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Meta-Analysis [J].
Ford, Alexander C. ;
Khan, Khurram J. ;
Achkar, Jean-Paul ;
Moayyedi, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (02) :167-176
[6]   Once-Daily Dosing vs. Conventional Dosing Schedule of Mesalamine and Relapse of Quiescent Ulcerative Colitis: Systematic Review and Meta-Analysis [J].
Ford, Alexander C. ;
Khan, Khurram J. ;
Sandborn, William J. ;
Kane, Sunanda V. ;
Moayyedi, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (12) :2070-2077
[7]   Efficacy of 5-Aminosalicylates in Ulcerative Colitis: Systematic Review and Meta-Analysis [J].
Ford, Alexander C. ;
Achkar, Jean-Paul ;
Khan, Khurram J. ;
Kane, Sunanda V. ;
Talley, Nicholas J. ;
Marshall, John K. ;
Moayyedi, Paul .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (04) :601-616
[8]   Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II trial [J].
Hanauer, SB ;
Sandborn, WJ ;
Kornbluth, A ;
Katz, S ;
Safdi, M ;
Woogen, S ;
Regalli, G ;
Yeh, C ;
Smith-Hall, N ;
Ajayi, F .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (11) :2478-2485
[9]   Once-daily, high-concentration MMX mesalamine in active ulcerative colitis [J].
Kamm, Michael A. ;
Sandborn, William J. ;
Gassull, Miguel ;
Schreiber, Stefan ;
Jackowski, Lechoslaw ;
Butler, Todd ;
Lyne, Andrew ;
Stephenson, David ;
Palmen, Mary ;
Joseph, Raymond E. .
GASTROENTEROLOGY, 2007, 132 (01) :66-75
[10]   Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial [J].
Kruis, W. ;
Kiudelis, G. ;
Racz, I. ;
Gorelov, I. A. ;
Pokrotnieks, J. ;
Horynski, M. ;
Batovsky, M. ;
Kykal, J. ;
Boehm, S. ;
Greinwald, R. ;
Mueller, R. .
GUT, 2009, 58 (02) :233-240